blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1434596

EP1434596 - ENHANCEMENT OF IMMUNE RESPONSES BY AGONIST 4-1BB-ANTIBODIES [Right-click to bookmark this link]
Former [2004/28]ENHANCEMENT OF IMMUNE RESPONSES BY 4-1BB-BINDING AGENTS
[2008/52]
StatusNo opposition filed within time limit
Status updated on  14.05.2010
Database last updated on 14.09.2024
Most recent event   Tooltip07.09.2012Lapse of the patent in a contracting state
New state(s): SE		published on 10.10.2012  [2012/41]
Applicant(s)For all designated states
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
200 First Street S.W.
Rochester, MN 55905 / US
[N/P]
Former [2009/28]For all designated states
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
200 First Street S.W.
Rochester, MN 55905 / US
Former [2004/28]For all designated states
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
200 First Street S.W.
Rochester, MN 55905 / US
Inventor(s)01 / CHEN, Lieping
2821 Char Lane, N.E.
Rochester, MN 55906 / US
02 / STROME, Scott, E.
428 Eagle Lane SW
Rochester, MN 55902 / US
 [2004/28]
Representative(s)Gassner, Wolfgang
Dr. Gassner & Partner mbB
Patentanwälte
Marie-Curie-Strasse 1
91052 Erlangen / DE
[N/P]
Former [2008/33]Gassner, Wolfgang
Dr. Gassner & Partner Patentanwälte Marie-Curie-Strasse 1
91052 Erlangen / DE
Former [2004/28]Gassner, Wolfgang, Dr.
Dr. Gassner & Partner Nägelsbachstrasse 49a
91052 Erlangen / DE
Application number, filing date02802551.809.10.2002
[2004/28]
WO2002US32364
Priority number, dateUS20010328004P09.10.2001         Original published format: US 328004 P
[2004/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03049755
Date:19.06.2003
Language:EN
[2003/25]
Type: A1 Application with search report 
No.:EP1434596
Date:07.07.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 19.06.2003 takes the place of the publication of the European patent application.
[2004/28]
Type: B1 Patent specification 
No.:EP1434596
Date:08.07.2009
Language:EN
[2009/28]
Search report(s)International search report - published on:US19.06.2003
(Supplementary) European search report - dispatched on:EP02.11.2004
ClassificationIPC:A61K38/16, A61K38/17, A61K39/395
[2004/28]
CPC:
A61K39/39 (EP,US); A61K39/0011 (US); A61K39/12 (EP,US);
A61K39/4611 (EP); A61K39/4615 (EP); A61K39/4622 (EP);
A61K39/464499 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P31/10 (EP); A61P31/12 (EP); A61P31/14 (EP);
A61P33/02 (EP); A61P35/00 (EP); C07K16/2878 (EP,US);
A61K2039/505 (EP,US); A61K2039/5152 (US); A61K2039/5154 (US);
A61K2039/5158 (US); A61K2039/55516 (EP,US); A61K2039/55522 (EP,US);
A61K2039/585 (EP,US); A61K2239/31 (EP); A61K39/00 (US);
C12N2710/20034 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/28]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:VERWENDUNG VON AGONISTISCHEN 4-1BB ANTIKÖRPERN ZUR ERHÖHUNG DER IMMUNANTWORT[2008/52]
English:ENHANCEMENT OF IMMUNE RESPONSES BY AGONIST 4-1BB-ANTIBODIES[2008/52]
French:AMELIORATION DES REPONSES IMMUNITAIRES PAR DES ANTICORPS AGONISTES LIANT 4-1BB[2008/52]
Former [2004/28]VERWENDUNG VON 4-1BB BINDENDEN AGENZIEN ZUR ERHÖHUNG DER IMMUNANTWORT
Former [2004/28]ENHANCEMENT OF IMMUNE RESPONSES BY 4-1BB-BINDING AGENTS
Former [2004/28]AMELIORATION DES REPONSES IMMUNITAIRES PAR DES AGENTS LIANT 4-1BB
Entry into regional phase24.04.2004National basic fee paid 
24.04.2004Search fee paid 
24.04.2004Designation fee(s) paid 
24.04.2004Examination fee paid 
Examination procedure24.04.2004Examination requested  [2004/28]
17.05.2005Despatch of a communication from the examining division (Time limit: M06)
18.11.2005Reply to a communication from the examining division
21.12.2006Despatch of a communication from the examining division (Time limit: M06)
09.05.2007Reply to a communication from the examining division
27.11.2008Cancellation of oral proceeding that was planned for 12.12.2008
27.11.2008Minutes of oral proceedings despatched
12.12.2008Date of oral proceedings
12.12.2008Date of oral proceedings (cancelled)
12.01.2009Communication of intention to grant the patent
12.05.2009Fee for grant paid
12.05.2009Fee for publishing/printing paid
Opposition(s)09.04.2010No opposition filed within time limit [2010/24]
Fees paidRenewal fee
25.10.2004Renewal fee patent year 03
27.10.2005Renewal fee patent year 04
27.10.2006Renewal fee patent year 05
29.10.2007Renewal fee patent year 06
27.10.2008Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.07.2009
BE08.07.2009
CY08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SE08.07.2009
SK08.07.2009
TR08.07.2009
BG08.10.2009
GR09.10.2009
IE09.10.2009
LU09.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
PT09.11.2009
[2012/41]
Former [2011/44]AT08.07.2009
BE08.07.2009
CY08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SK08.07.2009
TR08.07.2009
BG08.10.2009
GR09.10.2009
IE09.10.2009
LU09.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
PT09.11.2009
Former [2011/21]AT08.07.2009
BE08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SK08.07.2009
BG08.10.2009
GR09.10.2009
IE09.10.2009
LU09.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
PT09.11.2009
Former [2010/46]AT08.07.2009
BE08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SK08.07.2009
BG08.10.2009
GR09.10.2009
IE09.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
PT09.11.2009
Former [2010/25]AT08.07.2009
BE08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SK08.07.2009
BG08.10.2009
MC31.10.2009
PT09.11.2009
Former [2010/24]AT08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
SK08.07.2009
BG08.10.2009
PT09.11.2009
Former [2010/22]AT08.07.2009
CZ08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
BG08.10.2009
PT09.11.2009
Former [2010/20]AT08.07.2009
DK08.07.2009
EE08.07.2009
FI08.07.2009
NL08.07.2009
BG08.10.2009
PT09.11.2009
Former [2010/18]AT08.07.2009
FI08.07.2009
NL08.07.2009
BG08.10.2009
PT09.11.2009
Former [2010/16]AT08.07.2009
FI08.07.2009
NL08.07.2009
PT09.11.2009
Former [2010/10]AT08.07.2009
FI08.07.2009
NL08.07.2009
Former [2010/09]AT08.07.2009
FI08.07.2009
Former [2010/08]AT08.07.2009
Documents cited:Search[X]WO9936093  (ADVANCED RES & TECH INST [US], et al) [X] 1-52 * the whole document *;
 [X]WO0029582  (PACIFIC NORTHWEST RESEARCH INS [US], et al) [X] 1-52 * examples 1-5; pages 45-46 *;
 [X]WO0041508  (SINAI SCHOOL MEDICINE [US]) [X] 1-52 * pages 30, lins 26-30; page 33, lines 17-22; example *;
 [E]WO03006632  (CANVAC [CA], et al) [E] 1-52* the whole document *;
 [X]  - MELERO I ET AL, "AMPLIFICATION OF TUMOR IMMUNITY BY GENE TRANSFER OF THE CO-STIMULATORY 4-1BB LIGAND: SYNERGY WITH THE CD28 CO-STIMULATORY PATHWAY", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, (1998), vol. 28, no. 3, ISSN 0014-2980, pages 1116 - 1121, XP000914703 [X] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A
 [X]  - GUINN B-A ET AL, "4-1BBL COOPERATES WITH B7-1 AND B7-2 IN CONVERTING A B CELL LYMPHOMA CELL LINE INTO A LONG-LASTING ANTITUMOR VACCINE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, (1999), vol. 162, no. 8, ISSN 0022-1767, pages 5003 - 5010, XP000887237 [X] 1-52 * the whole document *
 [X]  - TAKAHASHI C ET AL, "Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, (19990501), vol. 162, no. 9, ISSN 0022-1767, pages 5037 - 5040, XP002238984 [X] 1-52 * the whole document *
 [Y]  - MELERO I ET AL, "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors", NATURE MEDICINE, NATURE PUBLISHING, CO, US, (199706), vol. 3, no. 6, ISSN 1078-8956, pages 682 - 685, XP002104261 [Y] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm0697-682
 [Y]  - BUBENIK J, "GENETICALLY ENGINEERED DENDRITIC CELL-BASED CANCER VACCINES (REVIEW)", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, (200103), vol. 18, ISSN 1019-6439, pages 475 - 478, XP001056627 [Y] 1-52 * the whole document *
 [Y]  - MELIEF C J M ET AL, "STRATEGIES FOR IMMUNOTHERAPY OF CANCER", ADVANCES IN IMMUNOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, (2000), vol. 75, ISSN 0065-2776, pages 235 - 282, XP001027072 [Y] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0065-2776(00)75006-1
 [PX]  - WILCOX R A ET AL, "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, (200203), vol. 109, no. 5, ISSN 0021-9738, pages 651 - 659, XP002238985 [PX] 1-52 * the whole document *

DOI:   http://dx.doi.org/10.1172/JCI200214184
 [PX]  - DIEHL L ET AL, "In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, (20020415), vol. 168, no. 8, ISSN 0022-1767, pages 3755 - 3762, XP002238986 [PX] 1-52 * the whole document *
International search[Y]WO0041508  (SINAI SCHOOL MEDICINE [US])
 [Y]  - KIM ET AL, "State-of-the-art review:therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8+T cells", J. HEMATOTHERAPY&STEM CELL RES., (200108), vol. 10, pages 441 - 449
 [Y]  - SICA ET AL, "Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential application in cancer therapy", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, (1999), vol. 47, pages 275 - 279
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.